Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 24, 2014 (12 years ago)

HydrALAZINE Hydrochloride Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Substance: Par Pharmaceutical, Inc. is recalling one lot of HydrALAZINE Hydrochloride tablets due to the presence of small aluminum particles.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

HydrALAZINE Hydrochloride Tablets, USP 25 mg, 100 count bottle Rx only, Distributed by: Par Pharmaceutical Companies, Inc. Spring Valley, NY10977

Drug: Hydralazine

Recalling firm
Par Pharmaceutical Inc.
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0332-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydralazine recalls

See all
Class III · Low risk

Hydralazine HCl Tablets

Failed Impurities/Degradation Specifications; during routine stability testing for impurities.

Terminated Impurity / degradation The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6441-61 D-0045-2025
Class II · Moderate risk

HydrALAZINE Hydrochloride Tablets

an out of specification result obtained during routine stability testing for Impurities. There is a remote possibility that use of this product could cause a medically reversible or transient adverse health consequences.

Terminated Impurity / degradation The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6440-61 D-0324-2024
Class III · Low risk

HydrALAZINE Hydrochloride Tablets

Failed Impurities/Degradation Specifications: Out of Specification (OOS) result in the repackaged product for Related Compounds (Impurities) at the 6-month time point.

Terminated Impurity / degradation Amerisource Health Services LLC D-0320-2024

Other recalls by Par Pharmaceutical Inc.

All 2014 recalls
Class II · Moderate risk

Glycopyrrolate Tablets

Failed Impurities/Degradation Specification: Presence of unknown impurity observed.

Terminated Impurity / degradation Par Pharmaceutical Inc. NDC 49884-0065-01 D-1071-2020
Class III · Low risk

PrediniSONE Tablets

Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg

Terminated Labeling / mix-up Par Pharmaceutical Inc. NDC 0603-5337-31 D-1035-2020
Class III · Low risk

Frovatriptan Succinate Tablets

Labeling: Incorrect or Missing Lot and/or Exp Date: Product incorrectly labeled with an expiration date of August 2022 rather than the correct expiration date of April 2022.

Terminated Labeling / mix-up Par Pharmaceutical Inc. NDC 0603-3718-34 D-0843-2020